Your browser doesn't support javascript.
loading
Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
Outeiro, Tiago F; Alcalay, Roy N; Antonini, Angelo; Attems, Johannes; Bonifati, Vincenzo; Cardoso, Francisco; Chesselet, Marie-Françoise; Hardy, John; Madeo, Graziella; McKeith, Ian; Mollenhauer, Brit; Moore, Darren J; Rascol, Olivier; Schlossmacher, Michael G; Soreq, Hermona; Stefanis, Leonidas; Ferreira, Joaquim J.
Afiliación
  • Outeiro TF; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Goettingen, Goettingen, Germany.
  • Alcalay RN; Max Planck Institute for Multidisciplinary Sciences, Goettingen, Germany.
  • Antonini A; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.
  • Attems J; Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Bonifati V; Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Cardoso F; Department of Neurosciences (DNS), Padova University, Padova, Italy.
  • Chesselet MF; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.
  • Hardy J; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Madeo G; Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • McKeith I; Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
  • Mollenhauer B; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Moore DJ; UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, United Kingdom.
  • Rascol O; Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Schlossmacher MG; UCL Movement Disorders Centre, University College London, London, United Kingdom.
  • Soreq H; Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong, China.
  • Stefanis L; Brain and Care Research Foundation, Rimini, Italy.
  • Ferreira JJ; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.
Mov Disord ; 38(7): 1127-1142, 2023 07.
Article en En | MEDLINE | ID: mdl-37156737
BACKGROUND: More than 200 years after James Parkinsondescribed a clinical syndrome based on his astute observations, Parkinson's disease (PD) has evolved into a complex entity, akin to the heterogeneity of other complex human syndromes of the central nervous system such as dementia, motor neuron disease, multiple sclerosis, and epilepsy. Clinicians, pathologists, and basic science researchers evolved arrange of concepts andcriteria for the clinical, genetic, mechanistic, and neuropathological characterization of what, in their best judgment, constitutes PD. However, these specialists have generated and used criteria that are not necessarily aligned between their different operational definitions, which may hinder progress in solving the riddle of the distinct forms of PD and ultimately how to treat them. OBJECTIVE: This task force has identified current in consistencies between the definitions of PD and its diverse variants in different domains: clinical criteria, neuropathological classification, genetic subtyping, biomarker signatures, and mechanisms of disease. This initial effort for "defining the riddle" will lay the foundation for future attempts to better define the range of PD and its variants, as has been done and implemented for other heterogeneous neurological syndromes, such as stroke and peripheral neuropathy. We strongly advocate for a more systematic and evidence-based integration of our diverse disciplines by looking at well-defined variants of the syndrome of PD. CONCLUSION: Accuracy in defining endophenotypes of "typical PD" across these different but interrelated disciplines will enable better definition of variants and their stratification in therapeutic trials, a prerequisite for breakthroughs in the era of precision medicine. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos